Research
Evercore ISI Initiates Coverage on PROCEPT BioRobotics With Outperform Rating, $30 Price Target
PROCEPT BioRobotics (PRCT) has an average rating of overweight and mean price target of $31.40, according to analysts polled by FactSet.
$PRCT
$PRCT
3 stories mentioning PRCTUpdated 22h ago
Every FINWIRES story that references PRCT, newest first.
Wire
PROCEPT BioRobotics Shares Drop After Downgrade From Leerink Partners
PROCEPT BioRobotics (PRCT) shares were down 5.8% in afternoon trading on Thursday after Leerink Partners downgraded the company's stock to market perform from outperform and adjusted the price target to $29 from $31.Trading volume stood at more than 1.8 million shares against a daily average of about 1.4 million.Price: $27.42, Change: $-1.68, Percent Change: -5.76%
$PRCT
Wire
Procept BioRobotics Enrolls 280 Patients in WATER IV Prostate Cancer Study
Procept BioRobotics (PRCT) enrolled 280 patients in the WATER IV study evaluating its Aquablation therapy against radical prostatectomy for prostate cancer.The company said Thursday it expects to present the primary endpoint results from the study at the American Urological Association annual meeting in spring 2027.Procept also received Investigational Device Exemption approval from the US Food and Drug Administration for a second randomized protocol comparing Aquablation therapy with active surveillance in men with Grade Group 1 and 2 prostate cancer. The study will enroll up to 333 patients globally, the company said.Both studies will follow patients for 10 years to assess disease control and quality-of-life outcomes, Procept said.Price: $26.12, Change: $-0.35, Percent Change: -1.30%
$PRCT
